{
    "clinical_study": {
        "@rank": "124503", 
        "arm_group": [
            {
                "arm_group_label": "Abametapir Lotion 0.74%", 
                "arm_group_type": "Active Comparator", 
                "description": "0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge."
            }, 
            {
                "arm_group_label": "Vehicle Lotion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge."
            }, 
            {
                "arm_group_label": "0.1% sodium lauryl sulfate", 
                "arm_group_type": "Other", 
                "description": "Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge."
            }, 
            {
                "arm_group_label": "Saline 0.9%", 
                "arm_group_type": "Other", 
                "description": "Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge."
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose of this study will be to determine the potential of abametapir lotion to induce\n      sensitization by repeated topical application to the healthy skin of humans under controlled\n      conditions."
        }, 
        "brief_title": "Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Head Lice", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or\n             older;\n\n          2. In the case of females of childbearing potential, are using an acceptable form of\n             birth control (oral/implant/injectable/transdermal contraceptives, intrauterine\n             device, condom with spermicide, diaphragm with spermicide, abstinence, partner's\n             vasectomy).  Abstinence or vasectomized partner are acceptable if the female subject\n             agrees to implement one of the other acceptable methods of birth control if her\n             lifestyle/partner changes;\n\n          3. If female of childbearing potential, have a negative urine pregnancy test at Day 1,\n             and are willing to submit to a pregnancy test at the end of study;\n\n          4. Are free of any systemic or dermatologic disorder, which, in the opinion of the\n             investigator, will interfere with the study results or increase the risk of adverse\n             events;\n\n          5. Are of any skin type or race, providing the skin pigmentation will allow discernment\n             of erythema;\n\n          6. Complete a patch study Medical Screening form as well as a Medical Personal History\n             form; and\n\n          7. Read, understand, and provide signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Have any visible skin disease at the application site which, in the opinion of the\n             investigative personnel, will interfere with the evaluation of the test site\n             reaction;\n\n          2. Are not willing to refrain from using topical/systemic analgesics such as aspirin\n             (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72\n             hours prior to and during the study (occasional use of acetaminophen will be\n             permitted);\n\n          3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during\n             the study, or systemic/topical antihistamines for 72 hours prior to and during the\n             study;\n\n          4. Are using medication which, in the opinion of the investigative personnel, will\n             interfere with the study results, including anti-inflammatory medications;\n\n          5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams,\n             ointments, lotions, or similar products on the back during the study;\n\n          6. Have psoriasis and/or active atopic dermatitis/eczema;\n\n          7. Are females who are pregnant, plan to become pregnant during the study, or are\n             breast-feeding a child;\n\n          8. Have a known sensitivity to constituents present in the material being evaluated;\n\n          9. Have damaged skin in or around the test sites, including sunburn, excessively deep\n             tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other\n             disfigurations of the test site;\n\n         10. Have received treatment for any type of internal cancer within 5 years prior to study\n             entry;\n\n         11. Have a history of, or are currently being treated for skin cancer;\n\n         12. Are currently participating in any other clinical trial;\n\n         13. Have any known sensitivity to adhesives; and/or\n\n         14. Have received any investigational treatment(s) within 4 weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062073", 
            "org_study_id": "Ha03-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abametapir Lotion 0.74%", 
                "intervention_name": "Abametapir Lotion 0.74% w/w", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.1% sodium lauryl sulfate", 
                "intervention_name": "0.1% sodium lauryl sulfate", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Saline 0.9%", 
                "intervention_name": "saline 0.9%", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "head lice", 
            "Hatchtech"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paramus", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07652"
                }, 
                "name": "TKL Reserach"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation", 
            "measure": "to evaluate the sensitizing potential of abametapir lotion using repeat insult patch test design", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hatchtech Pty Ltd", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "TKL Research, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Accelovance Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hatchtech Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}